109 related articles for article (PubMed ID: 28528747)
1. Selumetinib does not improve survival outcomes in NSCLC.
Das M
Lancet Oncol; 2017 Jun; 18(6):e313. PubMed ID: 28528747
[No Abstract] [Full Text] [Related]
2. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
3. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
Govindan R
J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
[No Abstract] [Full Text] [Related]
4. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract][Full Text] [Related]
5. Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib improves progression-free survival in NSCLC.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e10. PubMed ID: 29175151
[No Abstract] [Full Text] [Related]
7. Brigatinib effective in ALK-positive non-small-cell lung cancer.
Das M
Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
[No Abstract] [Full Text] [Related]
8. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
9. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib for children with plexiform neurofibromas.
Burki TK
Lancet Oncol; 2017 Feb; 18(2):e69. PubMed ID: 28089105
[No Abstract] [Full Text] [Related]
11. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
Huang B; Tian L; Talukder E; Rothenberg M; Kim DH; Wei LJ
JAMA Oncol; 2018 Jun; 4(6):874-876. PubMed ID: 29710201
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
14. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.
Abdel-Rahman O
Ther Adv Respir Dis; 2016 Jun; 10(3):265-74. PubMed ID: 26893312
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
18. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
[TBL] [Abstract][Full Text] [Related]
19. [TRUST study: general practice relevant data on erlotinib in NSCLC].
Knabl A
Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
[No Abstract] [Full Text] [Related]
20. BGB-283 Deemed Effective in Phase I Study.
Cancer Discov; 2016 Jul; 6(7):OF1. PubMed ID: 27267516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]